Last $1.58 USD
Change Today -0.02 / -1.25%
Volume 345.0K
IDRA On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 3:23 PM 05/25/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

167 Sidney Street

Cambridge, MA 02139

United States

Phone: 617-679-5500

Fax: 617-679-5592

Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates. Strategy The company’s business strategy focuses on the development of drug candidates for oncology and rare diseases. TLR Modulation Technology Platform The company’s TLR antagonist lead drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. The company’s primary drug candidate is IMO-8400, a novel synthetic oligonucleotide antagonist of TLR7, TLR8, and TLR9. The company is developing IMO-8400 for the treatment of certain genetically defined forms of B-cell lymphoma and for the treatment of rare diseases. The company is conducting a Phase 1 clinical trial of IMO-9200 in healthy subjects, as well as additional preclinical studies of IMO-9200 for a selected autoimmune disease. In addition, the company is planning to advance at least one of its TLR9 agonists, IMO-2055 or IMO-2125, into clinical development for intratumoral injection in combination with checkpoint inhibitors for selected oncology targets. IMO-8400 Development Program in Genetically Defined Forms of B-cell Lymphoma The company is developing IMO-8400 for the treatment of certain B-cell lymphomas in which the MYD88 L265P oncogenic mutation is present. MYD88 is an adaptor protein in the TLR signaling pathway that mediates TLR signaling. In 2014, the company initiated patient treatment in its ongoing open-label, dose-escalation Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström’s macroglobulinemia who have relapsed or were refractory to prior therapy. The company is also conducting an open-label, dose-escalation Phase 1/2 clinical trial of IMO-8400 in patients with DLBCL who have relapsed or were refractory to prior therapy. In 2014, the company entered into a collaboration with Abbott Molecular, Inc., or Abbott Molecular, for the development of a companion diagnostic that can be used to identify patients with the MYD88 L265P oncogenic mutation. Application of TLR Agonists in Immuno-Oncology The company’s pipeline of drug candidates includes IMO-2055 and IMO-2125, two TLR9 agonists that may have potential applications as immune therapies for the treatment of cancer. Program in Rare Diseases The company is planning to initiate clinical development of IMO-8400 for the treatment of rare diseases. The company has selected dermatomyositis and Duchenne muscular dystrophy (DMD), as the first non-cancer rare diseases for which it plans to develop IMO-8400. IMO-8400 Development Program for Dermatomyositis In August 2014, the company initiated a collaboration with The Myositis Association, or TMA, a U.S. patient advocacy organization focused on myositis, to advance the clinical development of IMO-8400 for the treatment of myositis. Under the collaboration, the company and TMA agreed to develop educational programs for patients and healthcare providers on TLR antagonism and opportunities to participate in clinical research. Program in Autoimmune Diseases IMO-9200 for Autoimmune Disease: The company has developed a second novel synthetic oligonucleotide antagonist of TLR7, TLR8, and TLR9, IMO-9200, as a drug candidate in clinical development for potential use in selected autoimmune disease indications. In 2014, the company initiated subcutaneous dosing in a Phase 1 clinical trial of IMO-9200 in healthy subjects. The company has also initiated additional preclinical studies of IMO-9200 for a selected autoimmune disease. Gene Silencing Oligonucleotide Technology to Target RNA The company is developing its GSOs to turn off the mRNA associated with disease causing genes. The company is undertaking an analysis of oncology and rare disease indications for development of drug candidates from its GSO technology. Collaboration Program in Vaccine Adjuvants The company has an exclusive license and research collaboration agreement with Merck Sharp & Dohme Corp. or Merck & Co., and gra

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDRA:US $1.58 USD -0.02

IDRA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDRA.
View Industry Companies
 

Industry Analysis

IDRA

Industry Average

Valuation IDRA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 381.2x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 257.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact IDERA PHARMACEUTICALS INC, please visit www.iderapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.